<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685786</url>
  </required_header>
  <id_info>
    <org_study_id>Weihong Chen06062018</org_study_id>
    <nct_id>NCT03685786</nct_id>
  </id_info>
  <brief_title>CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT</brief_title>
  <official_title>The Study of Autologous T Cells Expressing CD19 Chimeric Antigen Receptors Treatment of Minimal Residual Disease(MRD) of B Cell Malignancies and Then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then
      auto-HSCT
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study of the chimeric antigen receptor T cells (CART Cells) treatment for
      minimal residual disease(MRD) of B Cell Malignancies and then autologous hematopoietic stem
      cell transplantation(auto-HSCT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">September 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) treatment for the Patients with Minimal Residual Disease (MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT</measure>
    <time_frame>day 28</time_frame>
    <description>The incidence of conversion of minimal residual disease (MRD) to &lt;0.01% after CART19 therapy in patients with MRD of B Cell Malignancies during upfront treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia, Lymphocytic, Acute, B-Cell</condition>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>Experimental: CART19 cell and auto-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART19 cell and auto-HSCT</intervention_name>
    <description>Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10^7 CART19 cells, Day 1, 30% fraction: 1.5x10^7-1.2x10^8 CART19 cells, Day 2, 60% fraction: 3x10^7-2.4x10^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.</description>
    <arm_group_label>Experimental: CART19 cell and auto-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients with CD19+, B cell Acute Lymphocytic Leukemia(B-ALL), B cell Chronic
        Lymphocytic Leukemia(B-CLL), B cell Lymphoma，who have 0.01%≤MRD&lt;10% during upfront
        treatment 2. Patients must be within 12 months of initial B-ALL, B-CLL, B cell Lymphoma
        diagnosis 3. Patients must have a measurable or evaluable disease at the time of
        enrollment, which may include any evidence of disease including minimal residual disease
        detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis 4.
        Age 14 years to 75 years 5. Adequate organ function defined as:

          1. AST and ALT ≤ 3 times upper limit of normal range for age,

          2. Serum creatinine ≤ 1.6 mg/dl,

          3. Direct bilirubin ≤2.0 mg/dl,

          4. Adequate pulmonary function defined as ≤ grade 2 dyspnea and ≤ grade 2 hypoxia,

          5. Cardiac Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA. 6.
             Patients with CNS disease will be eligible if CNS disease is responsive to therapy 7.
             Expression of CD19 on leukemic blasts demonstrated by flow cytometry or
             immunohistochemistry of bone marrow or peripheral blood 8. Adequate performance status
             defined as ECOG Performance Status 0 or 1 9. Provides written informed consent 10.
             Subjects of reproductive potential must agree to use acceptable birth control methods,
             as described in protocol

        Exclusion Criteria:

          1. Active, uncontrolled infection

          2. Active hepatitis B or hepatitis C

          3. HIV Infection

          4. Class III/IV cardiovascular disability according to the New York Heart Association
             Classification

          5. Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on
             medical management within two weeks of enrollment

          6. Pregnant or nursing (lactating) women Patients with a known history or prior diagnosis
             of optic neuritis or other

          7. immunologic or inflammatory disease affecting the central nervous system, and
             unrelated to leukemia or previous leukemia treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weihong Chen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The second people's hospital of Shenzhen, The first affiliated hospital of Shenzhen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Du, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The second people's hospital of Shenzhen, The first affiliated hospital of Shenzhen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaochun Wan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weihong Chen, M.D., Ph.D.</last_name>
    <phone>0086-755-83366388</phone>
    <phone_ext>8199</phone_ext>
    <email>whitney-cindy@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Du, M.D., Ph.D.</last_name>
    <phone>0086-755-83366388</phone>
    <phone_ext>8197</phone_ext>
    <email>duxingz@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weihong Chen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihong Chen, M.D.,Ph.D.</last_name>
      <phone>0086-755-83366388</phone>
      <phone_ext>8199</phone_ext>
      <email>whitney-cindy@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Du, M.D.,Ph.D.</last_name>
      <phone>0086-755-83366388</phone>
      <phone_ext>8197</phone_ext>
      <email>duxingz@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

